SciClone Pharmaceuticals, Inc. (SciClone ) is a biopharmaceutical company engaged in the development and commercialization of therapeutics to treat life-threatening diseases. ZADAXIN, the Company’s brand of thymalfasin and its primary product, is sold in over 30 countries for the treatment of the hepatitis B virus (HBV) and the hepatitis C virus (HCV), certain cancers and as a vaccine adjuvant. The Company develops various pipelines of phase II drug candidates, including RP101 for the treatment of pancreatic cancer and SCV-07 for the treatment of HCV and for oral mucositis. Its DC Bead product is awaiting approval in China, for the treatment of liver cancer. The Company manufactures ZADAXIN, RP101 and SCV-07 through third-party contract manufacturers, and it conducts its research and development efforts principally through arrangements with clinical research sites, contract research organizations and universities.